Results 261 to 270 of about 80,161 (286)

Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials

Pharmacological Research, 2021
Luis E Simental-Mendia, Adriana Sanchez-Garcia, Mario Simental-Mendia   +2 more
exaly  

Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials

Pharmacological Research, 2020
Millán-Alanís Jm, Luis E Simental-Mendia, Adriana Sanchez-Garcia   +2 more
exaly  

Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence

Expert Opinion on Drug Metabolism and Toxicology, 2021
Christos Kontogiorgis, Georgios Poulentzas, Antonios Douros   +2 more
exaly  

The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis

Digestive and Liver Disease, 2022
Ning Xia, Yuzhen Liang
exaly  

Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus

Life, 2022
Toshiyuki Oshitari, Tomoaki Tatsumi, Yoko Takatsuna   +2 more
exaly  

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Lancet, The, 2022
Parminder Judge, Chih-Chin Liu, Doreen Zhu   +2 more
exaly  

[Sodium-glucose co-transporter 2 inhibitor for diabetes?].

Nederlands tijdschrift voor geneeskunde, 2016
Following initial expectations, raised by the results of the United Kingdom Prospective Diabetes Study, intervention studies aimed at tight glucose control did not reduce cardiovascular disease. The EMPA-REG OUTCOME, an empagliflozin intervention study in over 7,000 patients with type 2 diabetes mellitus and a history of cardiovascular disease, for the
openaire   +1 more source

Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors

European Journal of Heart Failure, 2021
Nikolaus Marx, Gianluigi Savarese, Marija Polovina   +2 more
exaly  

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus

Expert Opinion on Investigational Drugs, 2013
William N Washburn
exaly  

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

Diabetes Therapy, 2014
Sanjay Kalra, Kalra Sanjay
exaly